67,459 Shares in CVS Health Corporation $CVS Purchased by Osmosis Investment Management UK Ltd

Osmosis Investment Management UK Ltd purchased a new stake in CVS Health Corporation (NYSE:CVS) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 67,459 shares of the pharmacy operator’s stock, valued at approximately $6,979,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in CVS. Handelsbanken Fonder AB raised its holdings in CVS Health by 83.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock worth $112,729,000 after buying an additional 496,124 shares during the period. State Street Corp boosted its holdings in shares of CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after buying an additional 1,245,457 shares during the period. Legal & General Group Plc boosted its holdings in shares of CVS Health by 0.3% in the fourth quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock worth $738,777,000 after buying an additional 31,249 shares during the period. Deutsche Bank AG increased its position in shares of CVS Health by 28.4% in the fourth quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock worth $370,333,000 after acquiring an additional 1,031,998 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. acquired a new stake in shares of CVS Health during the second quarter valued at approximately $49,622,000. 80.66% of the stock is currently owned by institutional investors.

CVS Health Stock Down 0.0%

CVS Health stock opened at $93.01 on Monday. The firm has a market cap of $118.96 billion, a PE ratio of 24.61, a P/E/G ratio of 0.85 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The firm’s 50 day moving average price is $102.02 and its two-hundred day moving average price is $88.95. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same quarter last year, the business posted $1.81 EPS. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is presently 70.37%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CVS shares. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a research note on Thursday, August 6th. Barclays boosted their target price on shares of CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Mizuho raised their target price on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. UBS Group lifted their price target on CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Wall Street Zen raised CVS Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $107.17.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.